What Is Cartalax?
Cartalax research has positioned this tetrapeptide bioregulator as one of the most tissue-specific compounds in connective tissue biology — developed within the same peptide bioregulator research program that produced Epitalon and Pinealon, Cartalax demonstrates targeted regulatory effects on chondrocyte function, extracellular matrix synthesis, and cartilage-specific gene expression that distinguish it from broader tissue repair compounds and make it a precision research tool for musculoskeletal and connective tissue biology.
Cartalax (Ala-Glu-Asp-Gly, molecular weight approximately 390.35 Da) is a synthetic tetrapeptide bioregulator developed at the St. Petersburg Institute of Bioregulation and Gerontology by Vladimir Khavinson and colleagues — the same research team responsible for Epitalon (telomerase-activating tetrapeptide), Pinealon (neuroprotective tripeptide bioregulator), and Thymalin (thymic bioregulator). Cartalax was developed within the framework of peptide bioregulator theory — which proposes that short peptides derived from specific tissues act as tissue-specific gene expression regulators through direct interaction with chromatin and transcription factor networks. Cartalax was identified as the active peptide fraction from cartilage tissue extract, with research focus on its role as a cartilage-specific bioregulator — particularly in the context of age-related cartilage degradation, chondrocyte biology, and musculoskeletal tissue maintenance in preclinical models.
Mechanism of Action
Tissue-Specific Gene Expression Regulation in Chondrocytes
In alignment with peptide bioregulator theory, Cartalax is hypothesized to interact directly with DNA and chromatin structures in chondrocytes — the specialized cells responsible for maintaining cartilage extracellular matrix. Research has demonstrated that short peptide bioregulators can penetrate cell nuclei and interact with chromatin in a sequence-specific manner, influencing transcription factor binding and gene expression patterns in a tissue-restricted fashion. In chondrocytes specifically, Cartalax has been studied for its ability to normalize age-related declines in anabolic gene expression — including genes encoding collagen type II (the primary structural collagen of hyaline cartilage), aggrecan (the major cartilage proteoglycan), and other extracellular matrix components critical to cartilage biomechanical function.
Collagen and Proteoglycan Synthesis Regulation
Cartilage integrity depends on the continuous synthesis and organization of two primary extracellular matrix macromolecules: collagen type II fibrils (providing tensile strength) and aggrecan proteoglycan aggregates (providing compressive resistance through their hydrophilic glycosaminoglycan chains). Research has examined Cartalax’s ability to modulate the expression of collagen type II alpha-1 chain (COL2A1), aggrecan core protein (ACAN), and associated extracellular matrix genes in chondrocyte cell models and cartilage tissue — investigating whether peptide bioregulator-mediated gene regulation can restore the anabolic-catabolic balance that is disrupted in cartilage aging and disease.
MMP Activity Modulation
Matrix metalloproteinases (MMPs) — particularly MMP-1, MMP-3, MMP-13, and ADAMTS-4/5 — are the primary enzymes responsible for cartilage extracellular matrix degradation in osteoarthritis and aging. The balance between MMP-mediated catabolism and chondrocyte-mediated anabolism determines net cartilage maintenance or degradation. Research has examined Cartalax’s effects on MMP expression and activity in chondrocyte models under inflammatory and oxidative stress conditions — investigating whether peptide bioregulator treatment can shift this balance toward matrix preservation.
Chondrocyte Proliferation and Survival
Adult articular cartilage is avascular and has extremely limited regenerative capacity — mature chondrocytes divide slowly and the tissue depends on a fixed population of cells for long-term matrix maintenance. Age-related chondrocyte loss through apoptosis and senescence progressively compromises this maintenance capacity. Research has examined Cartalax’s effects on chondrocyte viability and proliferation — particularly under conditions of oxidative stress, inflammatory cytokine exposure, and mechanical loading — investigating whether tissue bioregulator treatment can preserve the chondrocyte population responsible for cartilage homeostasis.
TGF-β Signaling in Connective Tissue
Transforming growth factor-beta (TGF-β) is the primary anabolic growth factor in cartilage biology — driving chondrocyte matrix synthesis, suppressing MMP expression, and modulating chondrocyte differentiation state. Research has examined the relationship between Cartalax treatment and TGF-β signaling pathway activity in connective tissue — investigating whether peptide bioregulator-mediated gene expression changes operate through or parallel to TGF-β-responsive transcriptional programs.
Research Applications
Osteoarthritis and Cartilage Degeneration Research
The primary research application for Cartalax concerns cartilage biology in the context of age-related and disease-related degeneration. Osteoarthritis — the most prevalent joint disease globally — is characterized by progressive cartilage extracellular matrix degradation, chondrocyte loss, and subchondral bone remodeling driven by the shift toward catabolic gene expression in aging chondrocytes. Research has examined Cartalax in relevant cartilage degeneration models, investigating whether tissue-specific bioregulator treatment can slow cartilage matrix degradation, preserve chondrocyte viability, and maintain joint function in aging and disease models.
Chondrocyte Biology Research
Cartalax provides a tissue-specific research tool for studying chondrocyte gene expression regulation, extracellular matrix biology, and the mechanisms of chondrocyte aging — distinct from the broader tissue repair compounds like BPC-157 and TB-500 that act through systemic mechanisms rather than cartilage-specific gene regulatory pathways. Research has used Cartalax to investigate the molecular biology of chondrocyte homeostasis and the gene expression changes that distinguish healthy, aging, and osteoarthritic chondrocytes.
Peptide Bioregulator Research
Cartalax is a valuable model compound for investigating the fundamental mechanisms of peptide bioregulator biology — the proposed mechanism by which short tissue-derived peptides regulate gene expression through chromatin interaction. Research using Cartalax alongside other bioregulators (Epitalon in pineal/telomere biology, Pinealon in neural tissue, Thymalin in thymic biology) allows systematic investigation of the tissue-specificity determinants of peptide bioregulator action — probing whether short peptide sequence differences are sufficient to account for the tissue-specific gene regulatory profiles observed across the bioregulator class.
Musculoskeletal Aging Research
Age-related musculoskeletal decline involves not only cartilage degradation but also bone density loss, tendon and ligament collagen cross-linking changes, and muscle-connective tissue interface remodeling. Research has examined Cartalax in the context of broader musculoskeletal aging biology — investigating how cartilage-specific bioregulator treatment interacts with the systemic changes in connective tissue metabolism that characterize musculoskeletal aging.
Connective Tissue Injury and Repair Research
Cartilage’s limited intrinsic repair capacity means that even moderate injury can progress to degenerative changes over time. Research has examined Cartalax in models of cartilage injury — investigating whether tissue-specific bioregulator treatment can support the limited repair responses that do occur following cartilage damage and reduce the progression toward degenerative joint disease.
Cartalax in the AminoForge Longevity and Tissue Repair Research Catalog
Cartalax addresses musculoskeletal aging through cartilage-specific bioregulator mechanisms — distinct from but complementary to the broader tissue repair compounds in AminoForge’s catalog. Researchers investigating connective tissue and musculoskeletal biology may find it most productive when studied alongside: BPC-157 — a multi-tissue repair peptide studied for tendon, ligament, bone, and gastrointestinal healing through angiogenic and cytoprotective mechanisms — and TB-500, an actin-binding peptide studied for muscle and connective tissue repair through cell migration mechanisms. For longevity research combining cartilage bioregulator and telomere biology, Epitalon shares the bioregulator development origin and provides complementary aging mechanisms in non-cartilage tissues. For further reading see: Peptide bioregulator research and tissue-specific gene regulation (PubMed).
Shop Cartalax at AminoForge — ≥99% purity, third-party COA verified, USA manufactured, ships within 48 hours.
Formulation and Storage
Cartalax is available as a lyophilized powder. With a molecular weight of approximately 390.35 Da, it is one of the smallest research peptides available — comparable in size to Epitalon (390.35 Da) and significantly smaller than most research peptides. Its small size confers relative stability and ease of reconstitution. Standard storage at −20°C for lyophilized powder applies, with reconstituted solutions stored at 2–8°C and protected from light. Bacteriostatic water is the standard reconstitution vehicle. Research-grade purity should be verified at ≥99% by HPLC with mass spectrometry confirmation of the 390.35 Da molecular weight and the correct Ala-Glu-Asp-Gly sequence.
All products sold by AminoForge are intended exclusively for laboratory and research purposes. Not for human or veterinary consumption. Researchers are responsible for compliance with all applicable laws and regulations governing research compound use in their jurisdiction.